All In Biotech

NDA 203985 · Novartis Pharm

Afinitor Disperz

Everolimus · Oral · Kinase Inhibitor; mTOR Inhibitor Immunosuppressant

Accelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Aug 29, 2012

Approved uses

4

Original approval plus efficacy supplements

Registered trials

881

126 Phase 3, 57 recruiting

FAERS reports

49,652

38,412 serious, 10,729 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 1, 2026.

AFINITOR is a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) AFINITOR DISPERZ is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures. ( 1.6 ) 1.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer AFINITOR ® is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. 1.2 Neuroendocrine Tumors (NET) AFINITOR is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or...

Mechanism: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers and in tuberous sclerosis complex (TSC). Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiation factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis....

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • AFINITOR DISPERZ · EVEROLIMUS 3MG · TABLET, FOR SUSPENSION, ORAL · Prescription · TE AB
  • AFINITOR DISPERZ · EVEROLIMUS 5MG · TABLET, FOR SUSPENSION, ORAL · Prescription · TE AB
  • AFINITOR DISPERZ · EVEROLIMUS 2MG · TABLET, FOR SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Everolimus" as an intervention, any sponsor and status, largest first.

All 881 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death6,228
  • malignant neoplasm progression4,735
  • diarrhoea4,068
  • fatigue3,804
  • stomatitis3,178
  • nausea2,837
  • dyspnoea2,608
  • drug ineffective2,369
  • pyrexia2,132
  • decreased appetite2,124
  • vomiting2,103
  • rash1,991

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20051
20065
200715
200834
2009188
2010928
20111,441
20122,329
20132,124
20142,292
20153,957
20164,826
20174,020
20184,795
20194,734
20204,272
20213,441
20222,698
20232,530
20242,117
20251,589
20261,314

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Afinitor Disperz (Everolimus)

2024 spending

$2.8M

Beneficiaries

12

64 claims

Per beneficiary

$232,619

$619.67 per unit

View as table
YearSpending
2020$9,646,174
2021$8,602,849
2022$6,393,479
2023$5,349,230
2024$2,791,430

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,822 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.